Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 10/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15565880 | 0.94 | MAPT (0.56) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL9908262 | 0.90 | ALDH1A1 (0.58) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL1982944 | 0.90 | ALDH1A1 (0.58) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL8551794 | 0.87 | ALDH1A1 (0.69) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL5090074 | 0.87 | ALDH1A1 (0.75) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL8204708 | 0.87 | ALDH1A1 (0.75) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL8373505 | 0.85 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL3113016 | 0.85 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL8549614 | 0.85 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD | |
| SCHEMBL8374769 | 0.85 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027242-A1 | PET RADIOLIGANDS FOR IMAGING GLUTAMINYL CYCLASE ACTIVITY | UNIV VANDERBILT (US) | 2026-01-29 | — | — | US | disclosed |
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | WISTA LABORATORIES LTD. | 2011-07-14 | — | — | US | disclosed |
| EP-1601384-B1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | GE HEALTHCARE AS (NO) | 2010-09-22 | — | — | EP | disclosed |
| EP-1601384-B1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | GE HEALTHCARE AS (NO) | 2010-09-22 | — | — | EP | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| EP-1682113-B1 | INHIBITOR IMAGING AGENTS | GE HEALTHCARE LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20070104644-A1 | Inhibitor imaging agents | CUTHBERTSON ALAN | 2007-05-10 | — | — | US | disclosed |
| EP-1682113-A1 | INHIBITOR IMAGING AGENTS | GE Healthcare Limited (GB) | 2006-07-26 | — | — | EP | disclosed |
| EP-1601384-A1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | Amersham Health AS (NO) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005049005-A1 | INHIBITOR IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| WO-2004080492-A1 | METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS | AMERSHAM HEALTH AS (NO) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | MAPT, PRNP, MAP4 | ALDH1A1 2058/4885MAPT 1/4885SMN1; SMN2 1022/4885 |
| US-20260027242-A1 | PET RADIOLIGANDS FOR IMAGING GLUTAMINYL CYCLASE ACTIVITY | QPCT, GLRA1, GLS | ALDH1A1 2351/4885MAPT 3343/4885SMN1; SMN2 2657/4885 |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | S1PR5, LPAR5, S1PR1 | ALDH1A1 1328/4885MAPT 3005/4885SMN1; SMN2 148/4885 |
| US-20070104644-A1 | Inhibitor imaging agents | MMP3, MMP1, MMP10 | ALDH1A1 900/4885MAPT 1990/4885SMN1; SMN2 1476/4885 |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | DOHH, VGF, HNRNPH3 | ALDH1A1 1683/4885MAPT 3527/4885SMN1; SMN2 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.